Ensuring product safety with rapid, reliable contamination testing solutions for sterility and bioburden compliance.
Every year, contaminated products put millions of patients at risk, leading to severe health consequences. HelioWaveTM offers next-generation rapid testing solutions, helping manufacturers meet complex and expanding safety demands.
.jpg)
Paul is a founder of HelioWave. He is also a Professor in the Department of Microbial Pathogenesis and Immunology in the Texas A&M Health Center, and in the Department of Veterinary Pathobiology in the College of Veterinary Medicine at Texas A&M University. Paul holds degrees from Rice University (B.A., Mathematics and Political Science), Stanford (M.A., Religious Studies), and Cornell (Ph.D., Biochemistry, Molecular and Cell Biology), and completed postdoctoral training at MIT and the University of Washington. He has broad experience and training in molecular biology, cell biology, microbiology, and biochemistry, with specific expertise in host-pathogen interactions and biotechnology development. He has authored more than 50 peer-reviewed publications and his research has been supported by awards from the Bill & Melinda Gates Foundation, NIH, NSF, USDA, DTRA, and DARPA, as well as several other private foundations.
.jpg)
Arum is a founder of HelioWave. He is the Texas Instruments Professor of the Department of Electrical and Computer Engineering, the Chancellor’s EDGES Fellow, and the Presidential Impact Fellow of Texas A&M University. He also holds a joint appointment in the Department of Biomedical Engineering, is a Graduate Faculty of the Texas A&M Health Science Center, Faculty of the Texas A&M Institute for Neuroscience, and Faculty of Toxicology. He holds degrees from Seoul National University (B.S., Electrical Engineering), University of Cincinnati (M.S., Electrical Engineering), and Georgia Institute of Technology (Ph.D., Electrical Engineering). His research expertise is in the development of microfluidic, lab-on-a-chip, and organ-on-a-chip systems and their applications in synthetic biology, microbiology, host-pathogen interactions, infectious disease, and microbial bioproduction. He has authored more than 150 peer-reviewed publications and his research is supported by the Bill & Melinda Gates Foundation, NIH, NSF, DARPA, DTRA, ARL, ARO, USDA, as well as several other private foundations. He currently serves as the Editor-in-Chief for the journal Biomedical Microdevices, and also serves as an editor/editorial board member of many leading journals.
.jpg)
The company is led by Dr. Adrian Guzman, CTO and co-founder of HelioWave Technologies, who is responsible for technology development, R&D oversight, and contract execution. Dr. Guzman has 10+ years of experience in microfluidic and lab-on-a-chip device development, with 8+ years of that experience primarily being focused on developing highly integrated next-generation complex droplet microfluidic systems for screening and other applications. Dr. Guzman has 10 peer-reviewed publications relating to biological microfluidic assay development, six-sigma lean launch experience, and has participated in the NSF iCORPS program. He successfully led the acquisition of a Phase 1 DARPA-SBIR grant for his first venture which is now on a successful path toward market launch. He holds an undergraduate degree in biomedical engineering, a Master's in electrical and computer engineering, and a PhD in Interdisciplinary Engineering, all from Texas A&M University. Throughout these experiences he has collaborated extensively with researchers from various life science disciplines and has a proven track record in working with and leading multidisciplinary R&D teams.
.jpg)
The company’s technology development is currently led by Dr. Can Huang. He is the Chief Operation Officer of HelioWave Technologies, LLC., where he exploits his expertise in microfluidic system development and microfabrication technologies to develop novel instruments for the biopharmaceutical industry. Previously, he was a postdoctoral researcher in the NanoBio Systems Lab (Advisor: Prof. Arum Han) at Texas A&M University. He holds degrees from Tsinghua University (B.S., Electrical Engineering), Rice University (M.S., Electrical Engineering), and Texas A&M University (Ph.D., Electrical Engineering). His research focuses on developing microfluidic lab-on-a-chip systems for microorganisms, point-of-care diagnosis applications, as well as novel microsystems for biomedical applications. He has participated and is currently serving as a core researcher member in projects supported by the Bill & Melinda Gates Foundation, NIH, NSF, DARPA, and ARL. He is also leading a DARPA-funded SBIR Phase II project to develop HelioSAFE sterility detection system. These experiences have provided him with valuable multidisciplinary research experience and skill sets. He has also participated in the NSF-iCORP program in 2019 and received training and mentorship through interactions with the Texas A&M McFerrin Center for Entrepreneurship.
Dr. Chris Jones, CEO of HelioWave Technologies, is a health economics and venture capital expert with dual degrees in health economics and biology from Oxford. His research in IVF led to $100M in annual savings for the NHS, and he pioneered evidence-based fertility insurance, now used globally. He has held leadership roles at CSL Behring and the University of Vermont College of Medicine and serves as an advisor on healthcare, cybersecurity, and blockchain. A published author in NEJM and BMJ, he also holds board positions at Betaliq, HealthTechCapital, and Springboard Enterprises.
Dr. Jeong Oh serves as the primary research scientist at HelioWave Technologies, where he directs multiple R&D initiatives to accelerate next-generation sterility testing. With 8+ years of research experience in microfabrication, tissue-engineering, and microphysiological system development, Dr. Oh brings a unique blend of technical and translational expertise to HelioWave’s pipeline. Prior to joining the company, he earned his M.S. and Ph.D. in Biomedical Engineering at University of Southern California, investigating scalable, high-throughput assays for cancer therapy development, including metabolism-targeting and CAR natural killer cell therapies. Building on this robust background, Dr. Oh applies multidisciplinary perspectives to the design and validation of rapid contaminant detection solutions for advanced therapy medicinal products.
Can
Huang
COO & Founder
Adrian
Guzman
CTO & Founder
Arum
Han
Founder
Paul
de Figueiredo
Founder
Jeong
Oh
Research Scientist
Chris
Jones
Interim CEO
Join the pioneers in leveraging our rapid testing solutions for exceptional quality assurance.
